S1881 Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Interim Results for 2 Years From the ASSURE Study
Publication/Presentation Date
10-2024
Volume
119
Issue
10
First Page
1351
Last Page
1352
Published In/Presented At
Trivedi, Palak J. MBBS, MRCP1; Levy, Cynthia MD2; Kowdley, Kris V. MD, FACG3; Gordon, Stuart C. MD4; Bowlus, Christopher L. MD5; Londoño Hurtado, Maria Carlota MD6; Hirschfield, Gideon M. MD7; Gulamhusien, Aliya F. MD, MPH3; Lawitz, Eric J. MD8; Villamil, Alejandra MD9; de Guevara Cetina, Alma MD10; Mayo, Marlyn J. MD, FACG11; Younes, Ziad H. MD12; Shibolet, Oren MD13; Yimam, Kidist K. MD14; Pratt, Daniel S. MD15; Heo, Jeong MD, PhD16; Morgera, Ulrike MD17; Andreone, Pietro MD18; Kremer, Andreas E. MD19; Corpechot, Christophe MD20; Goel, Aparna MD21; Peyton, Adam DO22; Elbeshbeshy, Hany MD23; Crittenden, Daria B. MD24,*; Heusner, Carrie PhD24; Proehl, Sarah MD24; Zhou, Shuqiong24; McWherter, Charles A. PhD24. S1881 Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Interim Results for 2 Years From the ASSURE Study. The American Journal of Gastroenterology 119(10S):p S1351-S1352, October 2024. | DOI: 10.14309/01.ajg.0001036892.89042.29
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine
Document Type
Article